Market Place
Sourcing Support
All News #Library
Biotech
Protara Therapeutics Reveals 2025 Financials And Business Update
10 Mar 2026 //
GLOBENEWSWIRE
Protara sees 66% Bladder Cancer Response Rate at 6 Months
25 Feb 2026 //
FIERCE BIOTECH
TARA-002 Shows 68% CR at 6 Months in NMIBC Trial
23 Feb 2026 //
GLOBENEWSWIRE
Protara Therapeutics To Present Phase 2 TARA-002 Data
22 Jan 2026 //
GLOBENEWSWIRE
Protara Therapeutics Showcases 2026 Milestones And Updates
12 Jan 2026 //
GLOBENEWSWIRE
Protara Initiates Phase 3 Trial Of IV Choline Chloride
07 Jan 2026 //
GLOBENEWSWIRE
Protara Announces Closing of $75 Million Public Offering
08 Dec 2025 //
GLOBENEWSWIRE
Protara Therapeutics Shares Updated TARA-002 Data
03 Dec 2025 //
GLOBENEWSWIRE
Protara Therapeutics To Review Phase 2 ADVANCED-2 Trial Data
01 Dec 2025 //
GLOBENEWSWIRE
Protara Reports Strong Interim Ph2 STARBORN-1 Data For TARA-002
19 Nov 2025 //
GLOBENEWSWIRE
Protara Presents ADVANCED-2 Trial Data at SUO Meeting
17 Nov 2025 //
GLOBENEWSWIRE
Protara Therapeutics Wins 2026 Biospace Best Places To Work Award
04 Nov 2025 //
GLOBENEWSWIRE
Protara Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
01 Aug 2025 //
GLOBENEWSWIRE
Protara Therapeutics Announces Q1 2025 Results & Business Update
08 May 2025 //
GLOBENEWSWIRE
Protara Therapeutics Appoints Leonardo Viana Nicacio, M.D., as CMO
15 Apr 2025 //
GLOBENEWSWIRE
Protara’s stock doubles biotech divulges new bladder cancer data
06 Dec 2024 //
FIERCE BIOTECH
Protara Shares Positive Results from Ongoing TARA-002 Ph 2 Trial
05 Dec 2024 //
GLOBENEWSWIRE
Protara Therapeutics Hosts Call on Phase 2 ADVANCED-2 Trial Data
03 Dec 2024 //
GLOBENEWSWIRE
Protara to Present Phase 2 ADVANCED-2 Data in NMIBC 25th Meeting
15 Nov 2024 //
GLOBENEWSWIRE
Protara Therapeutics to Present at Guggenheim Healthcare Conference
06 Nov 2024 //
GLOBENEWSWIRE
Protara Announces Results From THRIVE-1 Study
09 Sep 2024 //
GLOBENEWSWIRE
Protara Announces Positive Data from TARA-002 Clinical Program in NMIBC
05 Apr 2024 //
GLOBENEWSWIRE
Protara Announces Presentation of Data from Phase 1a Trial of TARA-002
30 Nov 2023 //
GLOBENEWSWIRE
Protara Announces Dosing of First Patient in Phase 2 Trial of TARA-002
23 Oct 2023 //
GLOBENEWSWIRE
Protara begins subject dosing in Phase Ib ADVANCED-1EXP expansion trial
16 May 2023 //
CLINICAL TRIALS ARENA
Protara Announces Dosing of 1st Patients in Ph 1b ADVANCED-1EXP Trial TARA-002
15 May 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.